COMPASS PATHWAYS PLC Long-Term Debt
COMPASS PATHWAYS PLC (CMPS) had Long-Term Debt of $50.73 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-05
- 2026-06-30: Long-term Debt, Excluding Current Maturities $50.73M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $50.48M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $14.11M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $18.60M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $50.73M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $50.48M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $14.11M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $18.60M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $22.95M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $21.55M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $24.65M 10-K · filed 2026-03-24 |
| 2024-09-30 | $27.64M 10-Q · filed 2024-10-31 |
| 2023-12-31 | $28.76M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |